Stay updated on Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial page.

Latest updates to the Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedFooter updates: added 'Revision: v3.3.3' and removed references to 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2'.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check29 days agoNo Change Detected
- Check43 days agoChange DetectedPublications section description updated to clarify automatic PubMed population; page revision label updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check50 days agoChange DetectedThe page no longer displays the government funding/operating status notice; core study details and eligibility sections appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check64 days agoChange DetectedThe page shows only minor updates such as timestamp changes and small wording edits, with no changes to core content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check93 days agoChange DetectedUpdated operating-status notice and added Bone osteosarcoma topic; removed old revision tag and added new revision tag v3.2.0.SummaryDifference2%

- Check100 days agoChange DetectedPage revision updated from v3.0.2 to v3.1.0, indicating a version bump with no other substantive content changes.SummaryDifference0.0%

Stay in the know with updates to Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial page.